30-Apr-04
09:43 GNTA Genta lower on FDA staff comments (12.60 -1.83)
Stock trades down 12.6% following Reuters report that the FDA staff review says Genasense trial results could be "Falsely positive." (Briefing.com note: Our sources indicate the somewhat negative comments were expected and do not give a good indication regarding approvability).
Having sat on the sidelines and watched OSIP and GNTA, I don't think there is anything now that would persuade me to take a position in a bio-tech. Just pure speculation!
Added some 10 strike put flys for .30 and completed my 15/20/25/30 condor for pennies. So I'm okay if this thing stabilizes here or somehow pops over 16 (unlikely now, I gather). Otherwise, c'est la vie.
Is anybody selling out of the money calls? Still pretty high premium. Assuming that the company has to do another trial, it seems to be a pretty sure bet.